drugset / Trial / NCT06001086
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Phase 2
Recruiting
70 enrolled
The First Affiliated Hospital with Nanjing Medical University
First Affiliated Hospital of Wenzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer
Timeline
- Start
- 2023-11-01
- Primary completion
- 2026-08-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamb Vedotin | Unknown | 2 mg/kg | Intravenous |
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |